Back to search

Article

Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications

2024-06-13

Abstract excerpt

<h4>Objective</h4> To assess the prevalence of multiple sclerosis (MS) activity, as well as neurologic and non-neurologic immune-related adverse events (irAEs) in persons with MS (pwMS) treated with immune checkpoint inhibitors (ICIs) for cancer. <h4>Background</h4> ICIs are associated with irAEs and exacerbation of certain preexisting autoimmune diseases. PwMS are generally excluded from ICI clinical trials, so d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3b173029-a3fa-5b6b-be62-774293d0b0bb
DOI
10.1101/2024.06.13.24308608
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indicationsDOI 10.1101/2024.06.13.24308608
Select a neighboring publication to make it the new centre.